Barclays Raises Progyny Price Target to $27 After Q1 EPS Beat
Barclays raised its price target for Progyny to $27.00 from $23.00 and maintained an Overweight rating after the company reported Q1 EPS of $0.50, beating the $0.44 estimate. Progyny delivered record Q1 revenue of $328.5 million, repurchased 8.8 million shares since last November, and holds a $1.82 billion market capitalization.
1. Analyst Price Target Increase
Barclays increased Progyny’s price target to $27.00 from $23.00 and maintained an Overweight rating, signaling strong analyst confidence in the company’s growth prospects compared to sector peers.
2. Q1 2026 Financial Beat
In Q1 2026, Progyny reported earnings per share of $0.50 versus a $0.44 consensus estimate and achieved record revenue of $328.5 million, up from $324.04 million a year earlier, driven by robust demand for its fertility and family building solutions.
3. Share Repurchases Enhance Value
Since November, Progyny has repurchased 8.8 million shares, reducing its outstanding share count and returning capital to shareholders, which supports per-share metrics and reflects management’s confidence.
4. Market Capitalization and Performance
Trading around $23.25, Progyny’s shares sit within a 52-week range of $16.10 to $28.75, giving the company a market capitalization near $1.82 billion and reinforcing its position in the medical benefits management sector.